We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry.
- Authors
López-Sendón, José; Álvarez-Ortega, Carlos; Auñon, Pilar Zamora; Soto, Antonio Buño; Lyon, Alexander R; Farmakis, Dimitrios; Cardinale, Daniela; Albendea, Miguel Canales; Batlle, Jaime Feliu; Rodríguez, Isabel Rodríguez; Fraga, Olaia Rodríguez; Albaladejo, Ainara; Mediavilla, Guiomar; González-Juanatey, Jose Ramón; Monzonis, Amparo Martínez; Prieto, Pilar Gómez; González-Costello, José; Antolín, José María Serrano; Chamorro, Rosalía Cadenas; Fernández, Teresa López
- Abstract
Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking. Methods and results We prospectively studied 865 patients, aged 54.7 ± 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups of progressive myocardial damage/dysfunction were considered according to current guidelines: normal, normal biomarkers (high-sensitivity troponin T and N-terminal natriuretic pro-peptide), and left ventricular (LV) function; mild, abnormal biomarkers, and/or LV dysfunction (LVD) maintaining an LV ejection fraction (LVEF) ≥50%; moderate, LVD with LVEF 40–49%; and severe, LVD with LVEF ≤40% or symptomatic heart failure. Cardiotoxicity was defined as new or worsening of myocardial damage/ventricular function from baseline during follow-up. Patients were followed for a median of 24 months. Cardiotoxicity was identified in 37.5% patients during follow-up [95% confidence interval (CI) 34.22–40.8%], 31.6% with mild, 2.8% moderate, and 3.1% with severe myocardial damage/dysfunction. The mortality rate in the severe CTox group was 22.9 deaths per 100 patients-year vs. 2.3 deaths per 100 patients-year in the rest of groups, hazard ratio of 10.2 (95% CI 5.5–19.2) (P < 0.001). Conclusions The majority of patients present objective data of myocardial injury/dysfunction during or after cancer therapy. Nevertheless, severe CTox, with a strong prognostic relationship, was comparatively rare. This should be reflected in protocols for clinical and research practices. Open in new tab Download slide Open in new tab Download slide
- Publication
European Heart Journal, 2020, Vol 41, Issue 18, p1720
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehaa006